Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04216290
Title A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, the INSPIRE Study
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

bladder urothelial carcinoma

Therapies

Cisplatin + Doxorubicin + Methotrexate + Vinblastine

Durvalumab + Fluorouracil + Mitomycin C

Gemcitabine

Fluorouracil + Mitomycin C

Durvalumab + Gemcitabine

Cisplatin + Durvalumab

Cisplatin + Gemcitabine

Carboplatin + Gemcitabine

Cisplatin

Durvalumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.